Fournier Labs Report issue

For profit Phase 3 Phase 4
Founded: Carrigtwohill Ireland (2001)
Status: Acquired by Solvay (2005) → now Abbott (2009)

Organization Overview

First Clinical Trial
2001
NCT00283335
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Fournier Pharma | Institut Alfred Fournier | Laboratoires URGO

Active Ingredients

Drugs in Phase 4 Trials (4)

icosapent ethyl (vascepa) (1 trial)

neomycin (2 trials)

nystatin (mycostatin) (2 trials)

polymyxin b sulfate (poly-rx) (2 trials)

Drugs in Phase 3 Trials (2)

gemfibrozil (lopid) (1 trial)

miconazole (monistat) (1 trial)

Drugs in Other Trials (1)

sucrose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 4)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Heart Diseases (Phase 3)

Myocardial Ischemia (Phase 3)

Vaginitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7